CN113030340A - Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry - Google Patents
Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry Download PDFInfo
- Publication number
- CN113030340A CN113030340A CN202110387399.3A CN202110387399A CN113030340A CN 113030340 A CN113030340 A CN 113030340A CN 202110387399 A CN202110387399 A CN 202110387399A CN 113030340 A CN113030340 A CN 113030340A
- Authority
- CN
- China
- Prior art keywords
- saikosaponin
- chaihuang
- preparation
- bupleurum
- test solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000004896 high resolution mass spectrometry Methods 0.000 title claims abstract description 19
- 239000007791 liquid phase Substances 0.000 title claims abstract description 6
- 230000008878 coupling Effects 0.000 title claims abstract description 5
- 238000010168 coupling process Methods 0.000 title claims abstract description 5
- 238000005859 coupling reaction Methods 0.000 title claims abstract description 5
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 claims abstract description 108
- 229930192014 saikosaponin Natural products 0.000 claims abstract description 94
- 239000009855 chai-huang Substances 0.000 claims abstract description 71
- 241000202726 Bupleurum Species 0.000 claims abstract description 56
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 claims abstract description 40
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 39
- 229930182490 saponin Natural products 0.000 claims abstract description 38
- 150000007949 saponins Chemical class 0.000 claims abstract description 38
- 235000017709 saponins Nutrition 0.000 claims abstract description 38
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 21
- SXILFEBNQCRWAL-UHFFFAOYSA-N Saikosaponin-f Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C6(CO)CCC(C)(C)CC6C5=CC4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 SXILFEBNQCRWAL-UHFFFAOYSA-N 0.000 claims abstract description 20
- GNVUHIXVRODVRA-UHFFFAOYSA-N saikosaponin-b2 Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC5=C6CC(C)(C)CCC6(CO)C(O)CC45C)C2(C)CO)C(O)C(O)C1OC7OC(CO)C(O)C(O)C7O GNVUHIXVRODVRA-UHFFFAOYSA-N 0.000 claims abstract description 16
- UFEGAVYKHITZAC-RUCQNWDKSA-N (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aS,6bR,8S,8aS,12aS,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)C3=CC=C3[C@@H]5CC(C)(C)CC[C@]5(CO)[C@@H](O)C[C@@]43C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O UFEGAVYKHITZAC-RUCQNWDKSA-N 0.000 claims abstract description 15
- VJEMOEYSQDKAQF-MJKDWHOWSA-N Saikosaponin C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2C([C@H]3[C@](C4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VJEMOEYSQDKAQF-MJKDWHOWSA-N 0.000 claims abstract description 15
- VSVPCEFIECVNTB-UHFFFAOYSA-N Saikosaponin c Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(C)(C)CC5(C)C4C=CC67OCC8(CCC(C)(C)CC68)C(O)CC57C)OC2COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C1O VSVPCEFIECVNTB-UHFFFAOYSA-N 0.000 claims abstract description 15
- YYHHNGWWKYBCRQ-UHFFFAOYSA-N bupleuroside X Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 YYHHNGWWKYBCRQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- ZDKCXSMMRXSSDE-UHFFFAOYSA-N chikusakoside II Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 ZDKCXSMMRXSSDE-UHFFFAOYSA-N 0.000 claims abstract description 15
- VJEMOEYSQDKAQF-UHFFFAOYSA-N saikogenin E 3-O-beta-D-glucopyranosyl-(1?6)-[alpha-L-rhamnopyranosyl-(1?4)]-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 VJEMOEYSQDKAQF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 14
- UAUUFLADFXKYAU-WQPKRVEVSA-N (2R,3R,4S,5R,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-6-methyloxane-3,4,5-triol Chemical compound C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)[C@@H]3C=CC3=C5CC(C)(C)CC[C@]5(CO)[C@H](O)C[C@@]43C)[C@]2(C)CO)[C@H](O)[C@@H](O)[C@H]1O UAUUFLADFXKYAU-WQPKRVEVSA-N 0.000 claims abstract description 12
- PYJMYPPFWASOJX-UHFFFAOYSA-N 2-[4,5-dihydroxy-6-[[8-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-2-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 PYJMYPPFWASOJX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 12
- WSSVJIGMYVWUJL-WMYDXDAXSA-N (2R,3R,4S,5R,6R)-2-[[(1S,2S,4S,5R,8R,9R,10S,13S,14R,17S,18R)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@](CO)(C)[C@H](CC[C@@]2(C)[C@@]3(C[C@H](O)[C@]45CO[C@]3([C@@H]4CC(C)(C)CC5)C=C[C@H]32)C)[C@]3(C)CC1 WSSVJIGMYVWUJL-WMYDXDAXSA-N 0.000 claims abstract description 11
- WSSVJIGMYVWUJL-UHFFFAOYSA-N Prosaikogenin F Natural products OC1C(O)C(O)C(C)OC1OC1C(CO)(C)C(CCC2(C)C3(CC(O)C45COC3(C4CC(C)(C)CC5)C=CC32)C)C3(C)CC1 WSSVJIGMYVWUJL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000006286 aqueous extract Substances 0.000 claims abstract description 9
- WRYJYFCCMSVEPQ-MNIDVGFKSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,4r,4ar,6ar,6bs,8s,8as,14ar,14bs)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-MNIDVGFKSA-N 0.000 claims abstract description 8
- WRYJYFCCMSVEPQ-ORAXXRKOSA-N Saikosaponin b2 Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-ORAXXRKOSA-N 0.000 claims abstract description 8
- WRYJYFCCMSVEPQ-IPNFWLSTSA-N saikosaponin b1 Natural products C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)[C@@H]3C=CC5=C6CC(C)(C)CC[C@]6(CO)[C@@H](O)C[C@]45C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]1O WRYJYFCCMSVEPQ-IPNFWLSTSA-N 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 99
- 239000012085 test solution Substances 0.000 claims description 47
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 44
- 238000005303 weighing Methods 0.000 claims description 39
- 239000000523 sample Substances 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 33
- 229910021529 ammonia Inorganic materials 0.000 claims description 22
- 239000013558 reference substance Substances 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 18
- 235000019253 formic acid Nutrition 0.000 claims description 15
- 238000007789 sealing Methods 0.000 claims description 15
- 238000009210 therapy by ultrasound Methods 0.000 claims description 14
- WRYJYFCCMSVEPQ-WVKLOLBYSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,4r,6ar,6bs,8r,8as,14bs)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-tr Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@](C3[C@](C4[C@@]([C@@]5(C[C@@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-WVKLOLBYSA-N 0.000 claims description 12
- YDQIRODFTJGGMP-UHFFFAOYSA-N Prosapogenin Chemical compound C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC34)C)(CO)C1=CCC2C3(C)CC(O)C(O)C4(C)C(=O)OC1OC(CO)C(O)C(O)C1O YDQIRODFTJGGMP-UHFFFAOYSA-N 0.000 claims description 12
- ZNFRITHWVZXJRK-UHFFFAOYSA-N Vitalboside A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O ZNFRITHWVZXJRK-UHFFFAOYSA-N 0.000 claims description 12
- VTXFLUJNMHWAAT-UHFFFAOYSA-N alternoside VII Natural products CC1(C)CC(O)C2(CO)C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(=O)O)C(C)(C)C5CCC34C)C2C1 VTXFLUJNMHWAAT-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 239000012982 microporous membrane Substances 0.000 claims description 12
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 claims description 12
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 claims description 12
- 239000012488 sample solution Substances 0.000 claims description 11
- 230000005686 electrostatic field Effects 0.000 claims description 10
- 230000004580 weight loss Effects 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 8
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000001502 supplementing effect Effects 0.000 claims description 7
- BHFXAIXRWOFWOS-XRWUOUDGSA-N (2S,3R,4R,5R,6S)-2-[(2R,3S,4R,5R,6R)-6-[[(3S,4R,4aR,6aR,6bS,8S,8aS,12aS,14aR,14bR)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4,5-dihydroxy-2-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC=C4[C@@H]6CC(C)(C)CC[C@]6(CO)[C@@H](O)C[C@@]54C)[C@]3(C)CO)[C@H](O)[C@H]2O)[C@H](O)[C@H](O)[C@H]1O BHFXAIXRWOFWOS-XRWUOUDGSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 239000012088 reference solution Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001819 mass spectrum Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000010413 mother solution Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 16
- 241000510654 Bupleurum chinense Species 0.000 description 15
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- -1 saikosaponin ion Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 244000248416 Fagopyrum cymosum Species 0.000 description 2
- 235000010852 Fagopyrum cymosum Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- RHOHXGSADTZSDZ-UHFFFAOYSA-N saikosaponin K Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC5=C6CC(C)(C)CCC6(CO)C(O)CC45C)C2(C)CO)C(O)C(OC7OC(CO)C(O)C(O)C7C)C1O RHOHXGSADTZSDZ-UHFFFAOYSA-N 0.000 description 2
- QZMAEZWZCGBZFK-AOJWCAIYSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2s,3r Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QZMAEZWZCGBZFK-AOJWCAIYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 239000009849 Bupleurum root extract Substances 0.000 description 1
- 244000236521 Bupleurum rotundifolium Species 0.000 description 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000992149 Solidago decurrens Species 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- 240000007641 Spergula rubra Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention relates to a method for measuring the content of bupleurum characteristic components in bupleurum and a preparation thereof by liquid phase coupling high resolution mass spectrometry, in particular to a method for measuring the content of saikosaponin in bupleurum medicinal material decoction pieces and bupleurum extracts, such as aqueous extracts thereof or bupleurum yellow preparations. The CHAIHUANG preparation is selected from CHAIHUANG granule, CHAIHUANG capsule, CHAIHUANG tablet, CHAIHUANG oral liquid, and CHAIHUANG soft capsule; preferably, the Chaihuang preparation is selected from Chaihuang granule, Chaihuang capsule, and Chaihuang tablet. The saikosaponin comprises one or more of the following 13 saponins: saikosaponin A, saikosaponin B1, saikosaponin B2, saikosaponin C, saikosaponin D, saikosaponin F, saikosaponin G, saikosaponin H, saikosaponin I, nipagoside K, saikosaponin S, Prosapogenin D, and Prosapogenin F. The method can simultaneously determine the characteristic components of 13 bupleurum in a short time and quantify the components.
Description
Technical Field
The invention belongs to the technical field of medicines, relates to a method for measuring the quality of a traditional Chinese medicine and a preparation thereof, and particularly relates to a method for measuring the content of a characteristic component of radix bupleuri in a radix bupleuri medicinal material, decoction pieces and an extract thereof, such as an aqueous extract or a radix bupleuri preparation, by using a liquid phase coupling high-resolution mass spectrometry technology. The method can simultaneously measure the characteristic components of 13 bupleurum in 20 minutes and quantify the components.
Background
Bupleurum chinense (Bupleurii RADIX), a dried root of Bupleurum scorzonerifolium Willd, or Bupleurum scorzonerifolium DC, a plant of Umbelliferae, is collected in the first part of the Chinese pharmacopoeia 2020. According to the different characteristics, it is called "Bei chai Hu" and "nan chai Hu" respectively. Collected in spring and autumn, removed stems and leaves and silt, and dried.
The chaihuang preparation is prepared with bupleurum root and skullcap root as two kinds of Chinese medicinal materials, and may be granule, tablet, capsule, soft capsule, etc. Has the effects of clearing heat and relieving exterior syndrome, and is clinically used for treating wind-heat type common cold with symptoms of fever, general malaise, headache, blurred vision and sore throat. In addition, the chaihuang preparation also has the efficacy of clearing heat and diminishing inflammation, and is clinically used for upper respiratory tract infection, cold and fever.
Each 1000 pieces of Chaihuang tablet collected in the first part of China pharmacopoeia 2020 edition is prepared by extracting 1000g of radix bupleuri and 1000g of radix Scutellariae and adding a proper amount of auxiliary materials. Each 1000ml of Chaihuang oral liquid collected in the first part of the China pharmacopoeia 2020 edition is prepared by extracting 500g of radix bupleuri and 500g of radix scutellariae and adding a proper amount of auxiliary materials. Each 1000g of the Chaihuang granules collected by the national food and drug administration national drug Standard WS3-B-2009-95-2008 is prepared from 1250g of radix bupleuri and 90g of radix scutellariae extract by adding a proper amount of auxiliary materials. The Chaihuang capsule collected by the national food and drug administration national drug Standard YBZ02362006 is prepared from radix bupleuri and radix scutellariae, and each capsule contains more than 45mg of baicalin. These preparations all control their quality by baicalin content, and lack monitoring of bupleurum in the preparation.
The bupleurum component is mainly saikoponin, and is composed of a series of characteristic saponins, such as saikoponin A (Saikosaponin A), saikoponin B1(Saikosaponin B1), saikoponin B2(Saikosaponin B2), Saikosaponin C (Saikosaponin C), saikoponin D (Saikosaponin D), saikoponin F (Saikosaponin F), saikoponin G (Saikosaponin G), saikoponin H (Saikosaponin H), saikoponin I (Saikosaponin I), nipagin K (Nepasaikosaponin K), saikoponin S (Saikosaponin S), Prosapogenin D, Prosapogenin F, etc. 13 types, and the chemical structures and properties of these saponins are similar to each other than 13 types, and the chemical structures and physical and chemical properties of these saponins are not measured by conventional liquid chromatography using an ultraviolet detector while separating them.
Although there are reports in the literature on simultaneous determination of a few of the saponins, there is no method for simultaneous determination of 13 saikosaponin types.
For example, Wenshuang literature (Wenshuang et al, HPLC method for determining saikosaponin a, b in bupleurum root granule)1C, d and baicalin content, journal of drug analysis, 01 st 2017, page 148-152) describe the determination of saikosaponin a, b in bupleurum particles1C, d and baicalin content by HPLC. The method adopts SB-C18Chromatography column (250mm × 4.6mm, 5.0 μm) with acetonitrile (A) -0.01% phosphoric acid water solution (B) as mobile phase, gradient elution (0-30min, 30% A → 60% A; 30-35min, 60% A), flow rate of 1mL/min, and detection wavelength of 210 nm. As a result: ultrasonic extracting with 5% concentrated ammonia methanol solution for 30min to obtain saikosaponin a and saikosaponin b1C, d and baicaleinThe quantity concentration is respectively in the range of 3.6-36.0, 6.0-60.0, 8.4-84.0, 9.2-92.0 and 10.0-100.0 mug/mL, the linear relation is good (r is more than or equal to 0.9992); the method has good precision, stability and repeatability, and RSD is less than 2.0%; saikosaponin a, b1The average recovery rates of c, d and baicalin are 97.5%, 95.3%, 99.7%, 98.4% and 95.1%, and the RSD is less than 2.0%; saikosaponin a, b in 3 batches of samples1D and baicalin content ranges of 1.560-1.573, 7.501-7.587, 9.204-9.356 and 11.635-11.817mg/g respectively, and saikosaponin c is not detected. The authors of the literature believe that the method can be used to verify that saikosaponin a, b in bupleurum root particles1And c, d and baicalin content measurement can provide scientific basis for overall quality control of the Chaihuang granules.
Yan Jie literature (Jie, et al, HPLC determination of content of saikoside a, c, d in overground and underground parts of 4 Sichuan radix bupleuri, J. Chinese Experimental formulary, 13 th 2014, pages 73-76) describes a method for determining content of saikoside a, c, d in different varieties and different medicinal parts of Sichuan radix bupleuri. The method adopts Agilent TC-C18 chromatographic column (4.6mm multiplied by 250mm, 5 mu m), mobile phase acetonitrile-water, gradient elution, flow rate of 1mL/min, detection wavelength of 210nm and column temperature of 30 ℃. As a result, the saikosaponin a, c and d have good linear relations with peak areas in the ranges of 0.753-22.590, 0.461-13.830 and 0.726-21.780 mu g respectively, and the average sample adding recovery rates are 100.83%, 99.96% and 101.12% respectively. The authors of the literature believe that the difference in saikosaponin content is greater for different species and different medicinal parts.
The present inventors tried to adopt the above literature methods and found that they could not simultaneously measure the above 13 saikosaponins. Therefore, the skilled in the art expects to have new methods for determining the content of saikosaponin in bupleurum medicinal materials, decoction pieces and extracts thereof, such as aqueous extracts and bupleurum root preparations, especially for simultaneously determining the content of the 13 saikosaponin.
Disclosure of Invention
The invention aims to provide a method for measuring the content of saikosaponin in bupleurum medicinal materials, decoction pieces and extracts thereof, such as aqueous extracts and bupleurum root preparations, and particularly provides a method for simultaneously measuring the content of 13 saikosaponin in the bupleurum medicinal materials, the decoction pieces and the extracts thereof, such as aqueous extracts and bupleurum root preparations. The present inventors have surprisingly found that the chromatography-mass spectrometry detection of 13 saponins can be accomplished within 20 minutes by the method of the present invention. The present invention has been completed based on such findings.
Therefore, the invention provides a method for measuring the content of saikosaponin in bupleurum medicinal materials, decoction pieces and extracts thereof, such as aqueous extracts or bupleurum root preparations, which adopts a high performance liquid chromatography high resolution mass spectrometry method to simultaneously measure the saikosaponin in the bupleurum root preparations and calculate the content of the saikosaponin.
The method according to the first aspect of the present invention, wherein said chaihuang preparation is selected from the group consisting of chaihuang granules, chaihuang capsules, chaihuang tablets, chaihuang oral liquid, chaihuang soft capsules. Preferably, the Chaihuang preparation is selected from Chaihuang granule, Chaihuang capsule, and Chaihuang tablet.
The method according to the first aspect of the present invention, wherein the saikosaponin comprises one or more combinations selected from the following 13 saponins: saikosaponin A (Saikosaponin A), Saikosaponin B1(Saikosaponin B1), Saikosaponin B2(Saikosaponin B2), Saikosaponin C (Saikosaponin C), Saikosaponin D (Saikosaponin D), Saikosaponin F (Saikosaponin F), Saikosaponin G (Saikosaponin G), Saikosaponin H (Saikosaponin H), Saikosaponin I (Saikosaponin I), nipagin K (Nepasaikosaponin K), saikoponin S (Saikosaponin S), Prosapogenin D, Prosapogenin F.
The liquid phase coupled high resolution mass spectrometry can be selected from: waters QTof high-resolution mass spectrometry, Agilent iFunnel Q-TOF high-resolution mass spectrometry, the mo Fisher quadrupole-electrostatic field orbitrap high-resolution mass spectrometry (UPLC-Q active-MS), the mo Fisher ion well-orbitrip high-resolution mass spectrometry, SCIEX QTOF high-resolution mass spectrometry, AB Qtof high-resolution time-of-flight mass spectrometry, Shimadzu Q-TOF high-resolution mass spectrometry, and the like.
The method according to the first aspect of the present invention, wherein the chromatographic conditions of the liquid chromatography-mass spectrometry (such as ultra high performance liquid chromatography tandem electrostatic field orbitrap mass spectrometry) are as follows: the column was phenomenex C18 (2.1X 150mm, 1.7 μm), and 0.1% formic acid solution was used as mobile phase A and methanol was used as mobile phase B, and the elution was carried out in a gradient at a flow rate of 0.25 mL/min. The elution gradient was as follows: 0-1min, 2% B; 1.0-2.5min, 2% -60% B; 2.5-6.5min, 60% -90% B; 6.5-7.5min, 90% -100% B; 7.5-9.5min, 100% B; 9.5-9.6min, 100% -2% B; 9.6-15.0min, 12% B. The column temperature was 25 ℃ and the amount of sample was 5. mu.L.
The method according to the first aspect of the present invention, wherein the mass spectrometry conditions of the liquid chromatography-mass spectrometry (such as ultra performance liquid chromatography tandem electrostatic field orbitrap mass spectrometry) are as follows: mass spectrum conditions: the positive and negative ion online detection mode is characterized in that ESI source, ion source temperature is 300 ℃, and capillary temperature is 350 ℃; the voltage of the taper hole is 3.0 kV; sheath gas flow 50 psi; auxiliary gas flow 10 psi; the S-Lens RF is 30 percent, and the scanning range m/z is 110-800; resolution 75000.
The method according to the first aspect of the present invention, wherein the method for quantifying molecular weight and chemical formula of said 13 saponins in the determination of liquid chromatography-mass spectrometry (such as ultra high performance liquid chromatography tandem electrostatic field orbitrap mass spectrometry) is as listed below.
The method according to the first aspect of the present invention, wherein the preparation of the mixed reference solution for reference and the preparation of the standard curve are calculated as follows: and precisely weighing a proper amount of reference substances, wherein the sample weights are respectively as follows: 17.56mg of saikosaponin A, 115.46mg of saikosaponin B, 211.98mg of saikosaponin B, 12.84mg of saikosaponin C, 11.56mg of saikosaponin D, 13.86mg of saikosaponin F, 12.44mg of saikosaponin G, 13.55mg of saikosaponin H, 12.83mg of saikosaponin I, 4.91mg of nipagoside K, 13.88mg of saikosaponin S, 11.03mg of Prosapogenin D and 11.03mg of Prosapogenin F are prepared by dissolving with 80% methanol to obtain saikosaponin G497.6 μ G/mL, saikosaponin H542.0 μ G/mL, 1.2 μ G/mL of saikosaponin I, 25 μ G/mL of saikosaponin K, 25 μ G/mL of saikosaponin F, 555.2 μ G/mL of saikosaponin S, 3625 μ G/mL of saikosaponin B, 3632 μ G/mL of saikosaponin B, 2479.2 μ G/mL of saikosaponin D, 11.03mg of saikosaponin F, 11.6 μ G/mL of saikosaponin F, 78 μ G/mL of saikosaponin S, A control mother liquor of Prosapogenin D441.2 μ g/mL and Prosapogenin F441.2 μ g/mL; precisely sucking 750 μ L of each of the 13 reference mother solutions to 10mL volumetric flasks, metering to volume with 80% methanol to scale, and making into 13 saikosaponin mixed reference solutions containing saikosaponin A52.68 μ G/mL, saikosaponin B146.38 μ G/mL, saikosaponin B235.94 μ G/mL, saikosaponin C38.52 μ G/mL, saikosaponin D34.68 μ G/mL, saikosaponin F41.58 μ G/mL, saikosaponin G37.32 μ G/mL, saikosaponin H40.65 μ G/mL, saikosaponin I38.49 μ G/mL, nipagin K36.825 μ G/mL, saikosaponin S41.64 μ G/mL, Prosapogenin D33.09 μ G/mL, and Prosapogenin F33.09 μ G/mL; diluting 13 saikosaponin mixed reference substance solutions by 5 times, 10 times, 25 times, 50 times, 75 times, 100 times, 250 times, 500 times, 750 times and 1000 times respectively, injecting, and calculating a standard curve, wherein the standard curve is used for quantitative calculation of various saponins in the Chaihuang preparation.
The method according to the first aspect of the present invention, wherein the test solution of bupleurum root material to be used in the determination is prepared as follows: taking a 0.5g sample of radix bupleuri, precisely weighing, placing in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing, weighing, carrying out ultrasonic treatment (power 500W, frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking uniformly, and filtering by using a 0.22 mu m microporous membrane to obtain the Chinese medicinal composition.
The method according to the first aspect of the present invention, wherein the test solution for decocting Bupleurum chinense DC to be used in the measurement is prepared by the following method: decocting 10g of bupleuri radix in water twice for 4 hr each time, filtering decoction, mixing filtrates, and concentrating to obtain extract; taking a sample extract which is equivalent to 0.5g of radix bupleuri, precisely weighing, placing the sample extract in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W, frequency 35kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking uniformly, and filtering by using a 0.22 mu m microporous membrane to obtain the Chinese medicinal composition.
The method according to the first aspect of the present invention, wherein the test solution of a chaihuang preparation to be used in the assay is prepared as follows: taking a sample of the Chaihuang preparation which is equivalent to 0.5g of bupleurum containing medicinal material, precisely weighing, placing the sample in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W, frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, complementing the loss weight by using the methanol solution containing 5% concentrated ammonia test solution, shaking up, and filtering by using a 0.22 mu m microporous membrane to obtain the bupleurum containing medicinal material; alternatively, the method according to the first aspect of the present invention, wherein the preparation of the test solution of a faaiba preparation to be used in the assay is prepared by a faaiba preparation test solution modification preparation method comprising the following operations: taking a sample of the chaihuang preparation which is equivalent to 0.5g of bupleurum containing medicinal material, precisely weighing, placing the sample into a conical flask with a plug, adding 25ml of diethyl ether and 0.5ml of 10 percent sodium hydroxide, sealing the plug, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 10 minutes, filtering, washing residues with 20ml of diethyl ether, volatilizing the diethyl ether from the residues, precisely adding 25ml of methanol solution containing 5 percent concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, complementing the weight loss by methanol solution containing 5 percent concentrated ammonia test solution, shaking up, and filtering by a 0.22 mu m microporous membrane to obtain the chaihuang preparation.
The method according to the first aspect of the present invention is characterized in that when a liquid chromatography-mass spectrometry (such as ultra high performance liquid chromatography-tandem electrostatic field orbitrap high resolution mass spectrometry) is used for sample determination, 5 μ l of each sample solution is precisely absorbed, the sample solution is respectively injected into a high performance liquid chromatography-mass spectrometry instrument for determination, and the content of each saponin in the test solution is calculated by using a standard curve, so as to obtain the product.
The method of the invention obtains satisfactory technical effect, and especially can simultaneously determine the content of 13 saponins from bupleurum in the chaihuang preparation within a short time of 20 min.
Drawings
FIGS. 1-7 are ion diagrams of LC-MS analysis of 13 saikosaponin, in each of which SSS represents saikosaponin S, CF represents Prosapogenin F, SSCD represents Prosapogenin D, and other abbreviations have similar meanings.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible. The following examples further illustrate the invention without limiting it.
Test example 1: research on UPLC-Q active-MS content determination of characteristic component of radix bupleuri in Chaihuang preparation
The characteristic components of the bupleurum medicinal materials, decoction pieces and aqueous extracts thereof and the bupleurum root preparation are simultaneously measured by adopting an ultra-high performance liquid chromatography tandem electrostatic field orbit trap high resolution mass spectrometry (UPLC-Q active-MS) technology, and the chromatographic conditions and the mass spectrometry conditions are detailed below. According to UPLC-Q active-MS content determination methodology research aiming at saikosaponin characteristic components of the bupleurum root-yellow preparation, a content determination method is established. And samples of chaihuang preparations from multiple manufacturers were collected from all over the country for analysis.
1. Experimental medicinal materials
Samples of commercially available Bupleurum falcatum were collected in 70 batches, which included: 45 batches of bupleurum chinense medicinal materials (8 batches of the bupleurum chinense medicinal materials are adulterated), 11 batches of Tibetan bupleurum chinense medicinal materials, 4 batches of bupleurum chinense medicinal materials, 7 batches of bupleurum chinense medicinal materials, 1 batch of bupleurum scorzonerifolium medicinal materials and 2 batches of solidago decurrens medicinal materials, wherein part of the medicinal materials and the sources and batch numbers (or self-numbering) are detailed in the following table 1.
TABLE 1
2. Saponin reference substance
The detailed information of the reference substances of 13 saikosaponin detected by the invention is shown in the following table 2.
3. Preparation of mixed control solutions and preparation of standard curves:
and precisely weighing a proper amount of reference substances, wherein the sample weights are respectively as follows: 17.56mg of saikosaponin A, 115.46mg of saikosaponin B, 211.98mg of saikosaponin B, 12.84mg of saikosaponin C, 11.56mg of saikosaponin D, 13.86mg of saikosaponin F, 12.44mg of saikosaponin G, 13.55mg of saikosaponin H, 12.83mg of saikosaponin I, 4.91mg of nipagoside K, 13.88mg of saikosaponin S, 11.03mg of Prosapogenin D and 11.03mg of Prosapogenin F are prepared by dissolving with 80% methanol to obtain saikosaponin G497.6 μ G/mL, saikosaponin H542.0 μ G/mL, 1.2 μ G/mL of saikosaponin I, 25 μ G/mL of saikosaponin K, 25 μ G/mL of saikosaponin F, 555.2 μ G/mL of saikosaponin S, 3625 μ G/mL of saikosaponin B, 3632 μ G/mL of saikosaponin B, 2479.2 μ G/mL of saikosaponin D, 11.03mg of saikosaponin F, 11.6 μ G/mL of saikosaponin F, 78 μ G/mL of saikosaponin S, Prosapogenin D441.2 μ g/mL, Prosapogenin F441.2 μ g/mL. Precisely sucking 750 μ L of each of the 13 reference mother solutions to 10mL volumetric flasks, metering to volume with 80% methanol to scale, and making into 13 saikosaponin mixed reference solutions containing saikosaponin A52.68 μ G/mL, saikosaponin B146.38 μ G/mL, saikosaponin B235.94 μ G/mL, saikosaponin C38.52 μ G/mL, saikosaponin D34.68 μ G/mL, saikosaponin F41.58 μ G/mL, saikosaponin G37.32 μ G/mL, saikosaponin H40.65 μ G/mL, saikosaponin I38.49 μ G/mL, nipagin K36.825 μ G/mL, saikosaponin S41.64 μ G/mL, Prosapogenin D33.09 μ G/mL, and Prosapogenin F33.09 μ G/mL. Diluting 13 saikosaponin mixed reference substance solutions by 5 times, 10 times, 25 times, 50 times, 75 times, 100 times, 250 times, 500 times, 750 times and 1000 times respectively, injecting, and calculating a standard curve, wherein the standard curve is used for quantitative calculation of various saponins in the Chaihuang preparation.
4. Measurement conditions
An ultra-high performance liquid chromatography tandem electrostatic field orbit trap high resolution mass spectrometer (UPLC-Q active-MS, which can be called as a chromatography-mass spectrometer, LC-MS, UPLC-MS and the like in the invention) is adopted.
Chromatographic conditions are as follows: the column was phenomenex C18 (2.1X 150mm, 1.7 μm), and 0.1% formic acid aqueous solution was used as mobile phase A and methanol was used as mobile phase B, and the elution was carried out by gradient elution at a flow rate of 0.25 mL/min. The elution gradient was as follows: 0-1min, 2% B; 1.0-2.5min, 2% -60% B; 2.5-6.5min, 60% -90% B; 6.5-7.5min, 90% -100% B; 7.5-9.5min, 100% B; 9.5-9.6min, 100% -2% B; 9.6-15.0min, 12% B. The column temperature was 25 ℃ and the amount of sample was 5. mu.L.
Mass spectrum conditions: the positive and negative ion online detection mode is characterized in that ESI source, ion source temperature is 300 ℃, and capillary temperature is 350 ℃; the voltage of the taper hole is 3.0 kV; sheath gas flow 50 psi; auxiliary gas flow 10 psi; the S-Lens RF is 30 percent, and the scanning range m/z is 110-800; resolution 75000.
The molecular weight and chemical formula of each control are shown in table 2 below.
TABLE 2
| No | Name of Chinese | English name | Method for quantifying molecular weight | Chemical formula (II) | Reference supplier |
| 1 | Saikosaponin A | Saikosaponin A | 825.46419(+ HCOOH) | C42H68O13 | Chinese food and drug assay Research institute |
| 2 | Saikosaponin B1 | Saikosaponin B1 | 825.46419(+ HCOOH) | C42H68O13 | Lemeitian medicine | dester Biological organisms |
| 3 | Saikosaponin B2 | Saikosaponin B2 | 825.46419(+ HCOOH) | C42H68O13 | Lemeitian medicine | dester Biological organisms |
| 4 | Saikosaponin C | Saikosaponin C | 971.5221(+ HCOOH) | C48H78O17 | Lemeitian medicine | dester Biological organisms |
| 5 | Saikosaponin D | Saikosaponin D | 825.46419(+ HCOOH) | C42H68O13 | Chinese food and drug assay Research institute |
| 6 | Saikosaponin G | Saikosaponin G | 825.46419(+ HCOOH) | C42H68O13 | Lemeitian medicine | dester Biological organisms |
| 7 | Saikosaponin H | Saikosaponin H | 971.5221(+ HCOOH) | C48H78O17 | Lemeitian medicine | dester Biological organisms |
| 8 | Root of Chinese Thorowax Saponin K | Nepasaikosap onin K | 989.53267(+ HCOOH) | C48H80O18 | NATURE STANDARD |
| 9 | Saikosaponin S | Saikosaponin S | 987.51702(+ HCOOH) | C48H78O18 | The technology of Beijing Saibao includes Limited company |
| 10 | Saikosaponin I | Saikosaponin I | 971.5221(+ HCOOH) | C48H78O17 | Lemeitian medicine | dester Biological organisms |
| 11 | Prosapoge nin D | Prosaikogeni n D | 663.41137(+ HCOOH) | C36H58O8 | Lemeitian medicine | dester Biological organisms |
| 12 | Saikosaponin F | Saikosaponin F | 973.53775(+ HCOOH) | C48H80O17 | Lemeitian medicine | dester Biological organisms |
| 13 | Prosapoge nin F | Prosaikogeni n F | 617.40589 | C36H58O8 | The technology of Beijing Saibao includes Limited company |
5. Preparation and determination of samples
Preparing a bupleurum medicinal material test solution: taking a 0.5g sample of radix bupleuri, precisely weighing, placing in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing, weighing, carrying out ultrasonic treatment (power 500W, frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking uniformly, and filtering by using a 0.22 mu m microporous membrane to obtain the Chinese medicinal composition.
Preparation of a radix bupleuri water extract (namely decoction) test solution: decocting 10g of bupleuri radix in water twice for 4 hr each time, filtering the decoctions, mixing the filtrates, and concentrating to obtain extract. Taking a sample extract which is equivalent to 0.5g of radix bupleuri, precisely weighing, placing the sample extract in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W, frequency 35kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking uniformly, and filtering by using a 0.22 mu m microporous membrane to obtain the Chinese medicinal composition.
Preparing a chaihuang preparation test solution: weighing Bupleurum root extract sample 0.5g, placing in conical flask with plug, adding methanol solution 25ml containing 5% concentrated ammonia solution, sealing, weighing, ultrasonic treating (power 500W, frequency 40kHz) for 30min, taking out, cooling, weighing, supplementing the weight loss with methanol solution containing 5% concentrated ammonia solution, shaking, and filtering with 0.22 μm microporous membrane.
The determination method comprises the following steps: precisely sucking 5 μ l of each sample solution, respectively injecting into high performance liquid chromatography-mass spectrometer, measuring, and calculating content of each saponin in the test solution with standard curve.
6. Methodology specificity review
Under the above conditions of chromatography-mass spectrometry, 13 saikosaponin ion diagrams are shown in FIGS. 1-7. As can be seen from the figure, 13 saikosaponin were well separated. In the figure, SSS means saikosaponin S, CF means Prosapogenin F, SSCD means Prosapogenin D, and other abbreviations have similar meanings. Furthermore, all 13 saponins could be tested within 20min under the chromatography-mass spectrometry conditions described above in the present invention.
7. Linear relationship and quantitative limit
Selecting a Chaihuang preparation (No. 41 Chaihuang granules), adding 13 saikosaponin mixed reference substance solutions (1.333333333 times of the saikosaponin mixed reference substance solution), 2 times of the saikosaponin mixed reference substance solution (c), 4 times of the saikosaponin mixed reference substance solution (c), 10 times of the saikosaponin mixed reference substance solution (c), 13.33333333 times of the saikosaponin mixed reference substance solution (c), 20 times of the saikosaponin mixed reference substance solution (c), 40 times of the saikosaponin mixed reference substance solution (r), 100 times of the saikosaponin mixed reference substance solution (c) and 200 times of the saikosaponin mixed reference substance solution (c), making a matrix standard curve, and performing linear regression on the sample injection concentration (X, ng/L) by taking the peak area (Y) of a chromatographic peak of a compound to be detected as a vertical coordinate. The linear range, regression equation and correlation coefficient, the results are shown in table 4 below. The data of the lowest addition concentration point in the linear equation are used for calculating the detection limit of 13 saponins according to the signal-to-noise ratio of 3 times, and the quantitative limit of 13 saponins is calculated according to the signal-to-noise ratio of 10 times, and the result is shown in table 4. These results indicate that the chaihuang preparation still has excellent linear relationship after being added with the reference substance, and the detection limit and the quantification limit can meet the general requirements of drug analysis.
8. Methodological recovery and precision testing
Taking 0.125g, 0.25g, 0.5g and 9 parts in total of the bupleurum root preparation (bupleurum root particles with the number 40), respectively adding 50, 100 and 200 mu L of a mixed reference substance solution of the saikoside according to the low level, the middle level and the high level, wherein each added reference level is 3 parts in parallel, preparing a sample solution according to the method, measuring, and calculating the recovery rate and the relative standard deviation of each saikoside, which are shown in the table 3.
TABLE 3
The results in the above table on the recovery and precision of the process indicate that the process has a large fluctuation in the recovery of individual saponins and a relatively large standard deviation of the recovery of different saponins, which is not ideal from the viewpoint of pharmaceutical analysis. In order to overcome the above problems, the operation of the present invention for the item "preparation of a fasuvin preparation test solution" in "preparation and measurement of samples" described above in test example 1 is changed to the following manner (which may be referred to as "fasuvin preparation test solution modified preparation method" in the present invention): taking a sample of the chaihuang preparation which is equivalent to 0.5g of bupleurum containing medicinal material, precisely weighing, placing the sample into a conical flask with a plug, adding 25ml of diethyl ether and 0.5ml of 10 percent sodium hydroxide, sealing the plug, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 10 minutes, filtering, washing residues with 20ml of diethyl ether, volatilizing the diethyl ether from the residues, precisely adding 25ml of methanol solution containing 5 percent concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, complementing the weight loss by methanol solution containing 5 percent concentrated ammonia test solution, shaking up, and filtering by a 0.22 mu m microporous membrane to obtain the chaihuang preparation. The present inventors have surprisingly found that excellent process recovery and precision of all 13 saponins can be obtained when the above mentioned chaihuang preparation test solution is modified preparation method when preparing the test solution. In a supplementary test, supplementary test a, the above modified preparation method of the chaihuang preparation test solution was used for methodological recovery and precision tests: taking 0.125g, 0.25g, 0.5g and 9 parts in total of a fagopyrum preparation (fagopyrum cymosum granules with the number of 40), respectively adding saikosaponin mixed reference substance solutions (50, 100 and 200 mu L) according to the low, middle and high levels, wherein each added reference level is parallel to 3 parts, preparing a test sample solution according to the fagopyrum cymosum preparation test sample solution modification preparation method, measuring, and calculating the recovery rate and relative standard deviation of each saikosaponin; as a result, the precision (RSD) of the 13 saponins is in the range of 0.84% -2.37%, for example, the RSD of the saikosaponin G is 2.37%, the RSD of the Prosapogenin D is 1.51%, and the recovery rate of the 13 saponins is in the range of 89% -95%, for example, the recovery rates of the saikosaponin A measured three times are respectively 92.4%, 90.1% and 91.7%; this result indicates that the improved preparation method using the chaihuang preparation test solution can significantly improve the methodological recovery rate and precision. In a supplementary test, supplementary test B, referring to supplementary test a, but when the ether-sodium hydroxide in the modified preparation method of chaihuang preparation sample solution is changed into ether, i.e. no sodium hydroxide is added, the same methodology recovery rate and precision tests are carried out, and as a result, the precision of 13 saponins fluctuates within the range of 1.36-11.62%, for example, the precision of Prosapogenin F is 8.68%, indicating that sodium hydroxide is indispensable in the modified preparation method. In a supplementary test, supplementary test C, referring to supplementary test A, but when the ether in the ether-sodium hydroxide in the modified preparation method of the chaihuang preparation sample solution is changed into acetone with the same amount, the same methodology recovery rate and precision tests are carried out, and as a result, the precision of 13 saponins fluctuates within the range of 0.92-13.24%, for example, the precision of saikosaponin I is 5.61%, which indicates that the ether cannot be easily replaced in the modified preparation method. Therefore, in one embodiment of the present invention, when preparing the test solution of the faggot preparation, the above modified preparation method of the test solution of the faggot preparation is adopted. In a supplementary trial, supplementary trial D, the recovery and relative standard deviation of each saikosaponin was determined/calculated with reference to supplementary trial a but the tested bupleurum root preparation was bupleurum root capsule No. 47; as a result, the precision (RSD) of 13 saponins was in the range of 0.97% to 2.21%, for example, RSD of saikosaponin G was 1.85%, and the recovery rates of 13 saponins were in the range of 91% to 96%, for example, the recovery rates of saikosaponin A measured three times were 93.7%, 91.5%, and 94.4%, respectively. In a supplementary trial, supplementary trial E, the recovery and relative standard deviation of each saikosaponin was determined/calculated with reference to supplementary trial a but the tested bupleurum preparation was a number 50 bupleurum tablet; as a result, the precision (RSD) of 13 saponins was in the range of 1.14% -2.63%, for example, RSD of saikosaponin G was 2.14%, and the recovery rate of 13 saponins was in the range of 88% -94%, for example, the recovery rates of saikosaponin A measured three times were 92.3%, 89.2%, and 90.7%, respectively. Therefore, the method is suitable for measuring the content of 13 saponins in various bupleurum root preparations. In other supplementary experiments, it has been found that, in the above "preparation of the bupleurum medicinal material test sample solution" and "preparation of the bupleurum decoction test sample solution" in "5, preparation and determination of the sample", when the bupleurum medicinal material and the bupleurum decoction test sample are tested by using the two, the recovery rate can reach more than 97%, and the precision RSD is below 2%, which indicates that the methodological recovery rate and precision are excellent for the bupleurum medicinal material and the bupleurum decoction test sample.
9. Detection of Chaihuang preparation sample
52 samples of the chaihuang preparation series obtained by the invention, including 46 batches of granules, 3 batches of capsules and 3 batches of tablets, are selected and measured according to the operation method (including the operation of the chaihuang preparation test solution modification preparation method), and the measurement results of the content of the characteristic components in a part of typical chaihuang preparations are shown in the table 4 (unit: mu g/g).
TABLE 4
As can be seen from the results in the table, the LC-MS method can simultaneously determine the contents of 13 saponins in the Chaihuang granules, Chaihuang capsules and Chaihuang tablets.
10. Measurement result of radix bupleuri
The method is adopted to measure the contents of 13 saponins in the bupleurum medicinal material. The results show that 13 saikosaponin components have the highest saikosaponin a and highest saikosaponin d, the content of bupleurum chinense and bupleurum falcatum is higher than 100 mu g/g except for individual samples, the content of a and d of bupleurum chinense and bupleurum scorzonerifolium are obviously lower than that of bupleurum chinense, the content of saponins such as solidago virgaurea, starwort root and the like in other non-bupleurum genera are extremely low, and a small amount of bupleurum chinense or bupleurum chinense is. The Nepasaikosaponin K content is higher than that of other quality bupleurum (except part of adulterated bupleurum) by about 25-650 times, so the index can be used as an index component for distinguishing the bupleurum. The content of Prosapogenin D in the bupleurum chinense is found to be about 4 to 200 times higher than that of other bupleurum chinense, so that the index can be used as an index component for distinguishing the bupleurum chinense as a reference.
Comparing the changes before and after decocting bupleuri radix, the results show that after decocting, saikosaponin I, G, S, H, B1 and B2 are greatly increased, saikosaponin A, D is greatly reduced, and saikosaponin F, hypo-glycoside F and C are also reduced. Nepasaikosaponin K and hypoglycoside D also tended to decrease, but the magnitude was not large. Therefore, the results are more stable as a characteristic index.
In the present invention, for convenience of description, the term "before decocting" may be understood as "decoction pieces of medicinal materials", and the term "after decocting" may be understood as "extract"
The results of some bupleurum root herbs are shown in table 5a and table 5 b.
TABLE 5a
Continue to watch 5a (B1 ~ S)
Continuation table 5a (G-F)
TABLE 5b
Continue to watch 5B (B1 ~ S)
Continue to watch 5b (G-F)
The above-described embodiments are merely preferred embodiments for fully illustrating the present application, and the scope of the present application is not limited thereto. The equivalent substitution or change made by the person skilled in the art on the basis of the present application is within the protection scope of the present application. The protection scope of this application is subject to the claims.
Claims (10)
1. A method for determining saikosaponin content in bupleuri radix medicinal materials, decoction pieces and their extracts such as their aqueous extracts or CHAIHUANG preparation comprises simultaneously determining saikosaponin content in the bupleuri radix medicinal materials, decoction pieces and their extracts such as their aqueous extracts or CHAIHUANG preparation by liquid phase coupling high resolution mass spectrometry (such as UPLC-Q active-MS).
2. The method according to claim 1, wherein said Chaihuang preparation is selected from the group consisting of Chaihuang granules, Chaihuang capsules, Chaihuang tablets, Chaihuang oral liquid, Chaihuang soft capsules; preferably, the Chaihuang preparation is selected from Chaihuang granule, Chaihuang capsule, and Chaihuang tablet.
3. A method according to claim 1, wherein the saikosaponin comprises one or more combinations selected from the following 13 saponins: saikosaponin A (Saikosaponin A), Saikosaponin B1(Saikosaponin B1), Saikosaponin B2(Saikosaponin B2), Saikosaponin C (Saikosaponin C), Saikosaponin D (Saikosaponin D), Saikosaponin F (Saikosaponin F), Saikosaponin G (Saikosaponin G), Saikosaponin H (Saikosaponin H), Saikosaponin I (Saikosaponin I), nipagin K (Nepasaikosaponin K), saikoponin S (Saikosaponin S), Prosapogenin D, Prosapogenin F.
4. The method according to claim 1, wherein the chromatographic conditions of the ultra-high performance liquid chromatography tandem electrostatic field orbitrap high resolution mass spectrometry are as follows: the chromatographic column is phenomenex C18(2.1 × 150mm, 1.7 μm), 0.1% formic acid aqueous solution is used as mobile phase A, methanol is used as mobile phase B, and gradient elution is adopted with the flow rate of 0.25 mL/min; the elution gradient was as follows: 0-1min, 2% B; 1.0-2.5min, 2% -60% B; 2.5-6.5min, 60% -90% B; 6.5-7.5min, 90% -100% B; 7.5-9.5min, 100% B; 9.5-9.6min, 100% -2% B; 9.6-15.0min, 12% B; the column temperature was 25 ℃ and the amount of sample was 5. mu.L.
5. The method according to claim 1, wherein the mass spectrometry conditions of the ultra high performance liquid chromatography tandem electrostatic field orbitrap high resolution mass spectrometry are as follows: mass spectrum conditions: the positive and negative ion online detection mode is characterized in that ESI source, ion source temperature is 300 ℃, and capillary temperature is 350 ℃; the voltage of the taper hole is 3.0 kV; sheath gas flow 50 psi; auxiliary gas flow 10 psi; the S-Lens RF is 30 percent, and the scanning range m/z is 110-800; resolution 75000.
6. The method according to claim 1, wherein the method of quantifying molecular weight and chemical formula of said 13 saponins in ultra high performance liquid chromatography tandem electrostatic field orbitrap high resolution mass spectrometry assay is as described in the specification.
7. The method according to claim 1, wherein the preparation of the mixed reference solution and the preparation of the standard curve for reference are calculated as follows: and precisely weighing a proper amount of reference substances, wherein the sample weights are respectively as follows: 17.56mg of saikosaponin A, 115.46mg of saikosaponin B, 211.98mg of saikosaponin B, 12.84mg of saikosaponin C, 11.56mg of saikosaponin D, 13.86mg of saikosaponin F, 12.44mg of saikosaponin G, 13.55mg of saikosaponin H, 12.83mg of saikosaponin I, 4.91mg of nipagoside K, 13.88mg of saikosaponin S, 11.03mg of Prosapogenin D and 11.03mg of Prosapogenin F are prepared by dissolving with 80% methanol to obtain a solution containing 702.4 μ G/mL of saikosaponin A, 1618.4 μ G/mL of saikosaponin B, 2479.2 μ G/mL of saikosaponin B, 513.6 μ G/mL of saikosaponin C, 462.4 μ G/mL of saikosaponin D, 554.4 μ G/mL of saikosaponin F, 497.6 μ G/mL of saikosaponin G, 542.0 μ G/mL of saikosaponin H, 513.2 μ G/mL of saikosaponin I, 491.0 μ G/mL of nipagide K, 491.0 μ G/mL of saikosaponin F, Control mother liquor of saikosaponin S555.2 μ g/mL, Prosapogenin D441.2 μ g/mL, and Prosapogenin F441.2 μ g/mL; precisely sucking 750 μ L of each of the 13 reference mother solutions to 10mL volumetric flasks, metering to volume with 80% methanol to scale, and making into 13 saikosaponin mixed reference solutions containing saikosaponin A52.68 μ G/mL, saikosaponin B146.38 μ G/mL, saikosaponin B235.94 μ G/mL, saikosaponin C38.52 μ G/mL, saikosaponin D34.68 μ G/mL, saikosaponin F41.58 μ G/mL, saikosaponin G37.32 μ G/mL, saikosaponin H40.65 μ G/mL, saikosaponin I38.49 μ G/mL, nipagin K36.825 μ G/mL, saikosaponin S41.64 μ G/mL, Prosapogenin D33.09 μ G/mL, and Prosapogenin F33.09 μ G/mL; diluting 13 saikosaponin mixed reference substance solutions by 5 times, 10 times, 25 times, 50 times, 75 times, 100 times, 250 times, 500 times, 750 times and 1000 times respectively, injecting, and calculating a standard curve, wherein the standard curve is used for quantitative calculation of various saponins in the Chaihuang preparation.
8. The method according to claim 1, wherein the test solution of bupleurum medicinal material to be used in the determination is prepared by the following method: taking a 0.5g sample of radix bupleuri, precisely weighing, placing in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing, weighing, carrying out ultrasonic treatment (power 500W, frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking up, and filtering by using a 0.22 mu m microporous membrane to obtain the radix bupleuri extract; and/or
Wherein the method for preparing the test solution of the bupleurum water extraction (namely decoction) required to be used in the determination is as follows: decocting 10g of bupleuri radix in water twice for 4 hr each time, filtering decoction, mixing filtrates, and concentrating to obtain extract; taking a sample extract which is equivalent to 0.5g of radix bupleuri, precisely weighing, placing the sample extract in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W, frequency 35kHz) for 30 minutes, taking out, cooling, weighing again, supplementing the weight loss by using the methanol solution containing 5% concentrated ammonia test solution, shaking uniformly, and filtering by using a 0.22 mu m microporous membrane to obtain the Chinese medicinal composition.
9. The method according to claim 1, wherein the test solution of the chaihuang preparation to be used in the assay is prepared by the following method: taking a sample of the Chaihuang preparation which is equivalent to 0.5g of bupleurum containing medicinal material, precisely weighing, placing the sample in a conical flask with a plug, precisely adding 25ml of methanol solution containing 5% concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W, frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, complementing the loss weight by using the methanol solution containing 5% concentrated ammonia test solution, shaking up, and filtering by using a 0.22 mu m microporous membrane to obtain the bupleurum containing medicinal material; alternatively, the method according to the first aspect of the present invention, wherein the preparation of the test solution of a faaiba preparation to be used in the assay is prepared by a faaiba preparation test solution modification preparation method comprising the following operations: taking a sample of the chaihuang preparation which is equivalent to 0.5g of bupleurum containing medicinal material, precisely weighing, placing the sample into a conical flask with a plug, adding 25ml of diethyl ether and 0.5ml of 10 percent sodium hydroxide, sealing the plug, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 10 minutes, filtering, washing residues with 20ml of diethyl ether, volatilizing the diethyl ether from the residues, precisely adding 25ml of methanol solution containing 5 percent concentrated ammonia test solution, sealing the plug, weighing, carrying out ultrasonic treatment (power 500W and frequency 40kHz) for 30 minutes, taking out, cooling, weighing again, complementing the weight loss by methanol solution containing 5 percent concentrated ammonia test solution, shaking up, and filtering by a 0.22 mu m microporous membrane to obtain the chaihuang preparation.
10. The method according to claim 1, wherein when the ultra high performance liquid chromatography tandem electrostatic field orbitrap high resolution mass spectrometry is used for measuring the sample, 5 μ l of each sample solution is precisely absorbed, respectively injected into a high performance liquid chromatography-mass spectrometry instrument for measurement, and the content of each saponin in the test solution is calculated by using a standard curve, thus obtaining the saponin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110387399.3A CN113030340A (en) | 2021-04-09 | 2021-04-09 | Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110387399.3A CN113030340A (en) | 2021-04-09 | 2021-04-09 | Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113030340A true CN113030340A (en) | 2021-06-25 |
Family
ID=76456282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110387399.3A Pending CN113030340A (en) | 2021-04-09 | 2021-04-09 | Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113030340A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020168426A1 (en) * | 2000-10-25 | 2002-11-14 | Shen Ping Niang | Composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof |
| CN101062071A (en) * | 2007-06-18 | 2007-10-31 | 石任兵 | Total saponins from radix bupleuri extract and the preparing method thereof |
| CN103364496A (en) * | 2012-04-09 | 2013-10-23 | 天士力制药集团股份有限公司 | Method for simultaneously measuring content of four types of saikoside in bupleurum extract |
| CN104267109A (en) * | 2014-07-31 | 2015-01-07 | 甘肃中天药业有限责任公司 | Radix bupleuri medicinal material detection method |
| CN110201130A (en) * | 2019-03-06 | 2019-09-06 | 十堰市太和医院 | A kind of preparation of Xiaochaihutang extract and mass spectrum fingerprint pattern construction method |
| CN112526006A (en) * | 2020-10-20 | 2021-03-19 | 鉴甄检测技术（上海）有限公司 | Method for detecting saikosaponin components in minor bupleurum particles |
-
2021
- 2021-04-09 CN CN202110387399.3A patent/CN113030340A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020168426A1 (en) * | 2000-10-25 | 2002-11-14 | Shen Ping Niang | Composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof |
| CN101062071A (en) * | 2007-06-18 | 2007-10-31 | 石任兵 | Total saponins from radix bupleuri extract and the preparing method thereof |
| CN103364496A (en) * | 2012-04-09 | 2013-10-23 | 天士力制药集团股份有限公司 | Method for simultaneously measuring content of four types of saikoside in bupleurum extract |
| CN104267109A (en) * | 2014-07-31 | 2015-01-07 | 甘肃中天药业有限责任公司 | Radix bupleuri medicinal material detection method |
| CN110201130A (en) * | 2019-03-06 | 2019-09-06 | 十堰市太和医院 | A kind of preparation of Xiaochaihutang extract and mass spectrum fingerprint pattern construction method |
| CN112526006A (en) * | 2020-10-20 | 2021-03-19 | 鉴甄检测技术（上海）有限公司 | Method for detecting saikosaponin components in minor bupleurum particles |
Non-Patent Citations (7)
| Title |
|---|
| 刘逢芹等: "不同溶剂对黄芩-柴胡药对中的药效成分提出的影响", 《中药材》, vol. 32, no. 6, pages 900 - 903 * |
| 吴呈祥: "正柴胡饮活性成分的液质联用分析及其抗炎活性评价", 《中国优秀硕士学位电子期刊网》, no. 11, 15 November 2020 (2020-11-15), pages 66 - 71 * |
| 周平等: "HPLC法测定春柴胡中柴胡皂苷a、d的含量", 《中药材》, vol. 34, no. 12, pages 1903 - 1906 * |
| 田伟等: "高效液相色谱串联质谱同时测定柴胡配方颗粒中柴胡皂苷a、b1、b2、c的含量", 《中国药学杂志》 * |
| 田伟等: "高效液相色谱串联质谱同时测定柴胡配方颗粒中柴胡皂苷a、b1、b2、c的含量", 《中国药学杂志》, vol. 51, no. 23, 8 December 2012 (2012-12-08), pages 2068 - 2071 * |
| 郭敏娜等: "基于HPLC-Q-TOF-MS技术的柴胡化学成分分析", 《中草药》 * |
| 郭敏娜等: "基于HPLC-Q-TOF-MS技术的柴胡化学成分分析", 《中草药》, vol. 47, no. 12, 28 June 2016 (2016-06-28), pages 2044 - 2052 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111624271B (en) | Liquid chromatography method for detecting corresponding substance of peony and licorice decoction, standard fingerprint spectrum and application | |
| CN110907550B (en) | Method for simultaneously detecting contents of six components in infant lung-ventilating and cough-relieving granules | |
| CN113063885B (en) | Composition for preparing Baoyuan decoction, baoyuan decoction product and fingerprint spectrum measuring and quality detecting method thereof | |
| CN114280209A (en) | Method for establishing fingerprint of heat-clearing cough-relieving oral liquid for children and fingerprint thereof | |
| CN108918696B (en) | Establishment method and quality control method of spleen-tonifying and lung-benefiting prescription fingerprint | |
| CN110988198A (en) | Content determination method of bi-tong ning capsules | |
| CN109115904B (en) | Construction method and application of UPLC fingerprint of Dingkundan | |
| CN110954645A (en) | Detection method of high-quality Sihuang dysentery stopping granules | |
| CN113030340A (en) | Method for measuring content of characteristic components of radix bupleuri in radix bupleuri and preparation thereof by liquid phase coupling high-resolution mass spectrometry | |
| CN113759011B (en) | Method for establishing characteristic spectrum of starwort root and preparation thereof | |
| CN111398505B (en) | Method for simultaneously detecting contents of five components of traditional Chinese medicine for treating infantile enuresis | |
| CN110082460B (en) | Quality detection method of Jingshu granules | |
| CN114088823A (en) | Method for measuring content of multi-index components in Tongtian oral liquid | |
| CN115266955A (en) | Method for detecting content of ingredients in deafness capsule based on one-test-multiple evaluation method | |
| CN108061772B (en) | Quality detection method of daphne preparation for treating cold asthma | |
| CN101647997A (en) | Influenza Shufeng capsule and preparation method and quality control method thereof | |
| CN113484427B (en) | Determination method and application of amygdalin in dampness-resolving toxin-vanquishing composition | |
| Huang et al. | Simultaneous UPLC analysis of three major flavonoids in granule decoctions of Fructus aurantii-type formulae | |
| CN114689729B (en) | Detection method of flavonoid glycoside component in Jingfeng particles | |
| CN115634252B (en) | Diuretic and quality control method thereof | |
| CN110927303B (en) | HPLC (high performance liquid chromatography) characteristic spectrum of Shuyanqing spray, construction method and application | |
| CN113588815B (en) | Method for simultaneously detecting content of multiple active ingredients in Rupishu capsule | |
| CN111679012B (en) | Preparation method of salvia miltiorrhiza extract and composition thereof | |
| CN102068599A (en) | Quality control method for phlegm eliminating and asthma relieving cough syrup | |
| CN115436524A (en) | Detection method and application of ginsenosides Rg1, re and Rb1 in channel warming decoction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No. 25, Science Park Road, Changping District, Beijing 102206 Applicant after: Beijing Institute of Drug Inspection (Beijing Vaccine Inspection Center) Address before: Beijing Institute for drug control, No.25, Zhongguancun Life Science Park, Beiqing Road, Changping District, Beijing, 102206 Applicant before: BEIJING INSTITUTE FOR DRUG CONTROL |
|
| CB02 | Change of applicant information |